ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

KPTI Karyopharm Therapeutics Inc

1.52
0.04 (2.70%)
Last Updated: 11:08:09
Delayed by 15 minutes

Period:

Draw Mode:

Volume 292,551
Bid Price 1.52
Ask Price 1.53
News -
Day High 1.5401

Low
0.6174

52 Week Range

High
4.87

Day Low 1.43
Company Name Stock Ticker Symbol Market Type
Karyopharm Therapeutics Inc KPTI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.04 2.70% 1.52 11:08:09
Open Price Low Price High Price Close Price Prev Close
1.45 1.43 1.5401 1.48
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
998 292,551 $ 1.50 $ 439,871 - 0.6174 - 4.87
Last Trade Time Type Quantity Stock Price Currency
11:08:34 1 $ 1.53 USD

Karyopharm Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
174.9M 115.07M - 146.03M -143.1M -1.24 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Karyopharm Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KPTI Message Board. Create One! See More Posts on KPTI Message Board See More Message Board Posts

Historical KPTI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.391.5451.341.42774,5230.139.35%
1 Month1.331.701.111.391,310,9940.1914.29%
3 Months0.8161.950.6554991.281,810,0330.70486.27%
6 Months1.341.950.61741.121,438,4920.1813.43%
1 Year3.464.870.61741.862,034,991-1.94-56.07%
3 Years10.3014.730.61744.992,191,119-8.78-85.24%
5 Years5.6529.610.61748.352,021,839-4.13-73.10%

Karyopharm Therapeutics Description

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's lead compound, XPOVIO(R) (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade(R) (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Your Recent History

Delayed Upgrade Clock